Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Mller MN, et al
The authors suggested that insurance barriers, cultural beliefs and concerns about side effects may play a role in this discrepancy, echoing findings from prior research showing lower uptake of GLP-1 RAs among black, Hispanic and Asian patients
This growth trajectory is propelled by extensive label expansions, expanding payer coverage, and broadening clinical-guideline endorsements that position glucagon-like peptide-1 (GLP-1) agonists as first-line or early combination choices in diabetes, obesity, and cardiovascular risk reduction
This challenges longstanding assumptions about brain metabolism and opens new avenues for treating metabolic brain disorders
Tian C, Liu Y, Li Z, et al
The gradual buildup ensures that your digestive system adapts to the hormone-mimicking action of semaglutide, reducing the likelihood of discomfort